Cohen Milstein Sellers & Toll PLLC served as lead counsel in this case, which resulted in a settlement of more than $11.2 million.  The case involved Defendants’ artificially inflating the price of POZEN stock by concealing and denying the fact that POZEN’s potential product line of drugs designed for the treatment of migraine was not approvable by the Food and Drug Administration.